ARKAY Therapeutics, Logo

(609) 362-6818

Follow Us:LinkedIn

Management Team

Stanley Schwartz

Stanley Schwartz, M.D.


Chief Medical Advisor

Emeritus Associate Professor of Medicine, University of Pennsylvania

Dr. Stan Schwartz is a renowned endocrinologist, an expert and a key opinion leader in diabetes and cardiometabolic syndrome. Dr. Schwartz developed the pancreatic 'beta-cell-centric' concept for not only reclassifying diabetes but more importantly for eficient clinical management by stratifying patients based on the mechanisms and defects that contribute to beta cell dysfunction. 

Read More

Dr. Martin Ogletree

Martin Ogletree, Ph.D.

Chief Scientific Advisor

Former Distinguished Research Fellow & Director of Thrombosis Research, Metabolic &
Cardiovascular Drug Discovery, Bristol-Myers Squibb and Merck

Dr. Martin Ogletree led thrombosis research in Cardiovascular Drug Discovery at Merck Research Labs and at Bristol-Myers Squibb (BMS). At Merck he also led target identification and validation for the cardiovascular franchise. At BMS he led the team that advanced ELIQUIS (apixaban) in drug discovery, preclinical and early clinical development. 

Read More

Board Members & Advisors

Dr. Ravi Kumar

Ravi Kumar, Ph.D.

Board Member and Chairman, Adjunct Professor, New York University, New York, NY

Dr. Ravi Kumar is the founder of ARKAY Therapeutics. He served as the CEO and Scientific Director from June 2014 until November 2019. He founded ARKAY with a mission to provide sustained glycemic control for Type 2 diabetes patients. Dr. Kumar has a unique combination of drug discovery and development expertise in metabolic, cardiovascular, and chronic inflammatory diseases with over 25 years of pharmaceutical industry experience in multiple companies including Pfizer. He is the inventor of ARKAY's U.S. patent "Formulations and Methods for Treating Metabolic Syndrome."  

 Read More

Dr. Alan Lewis

Alan J. Lewis, Ph.D.

President and CEO, DiaVacs

Board Member

Dr. Alan J. Lewis is currently the President, CEO and board member of DiaVacs, a Type 1 diabetes company. DiaVacs is developing products to reverse the onset of autoimmune diseases by reinducing tolerance into the patient's immune system. Dr. Lewis is a serial entrepreneur with over 40 years experience in diabetes research. He has served as president of JDRF as well as head of research at Wyeth-Ayerst Research. 

Read More

Dr. Nancy Motola

Nancy C. Motola, PhD, RAC

Former Senior Vice President, Regulatory & Quality, Alexion Pharmaceuticals Inc.


Dr. Nancy C. Motola, RAC, has over 30 years' experience in the Pharmaceutical Industry, encompassing both small molecules, biologics, and many therapeutic areas, in regulatory affairs and quality assurance, as well as chemical development/manufacturing. Through her consulting company, Pharma Regulatory Connection, she provides strategic Regulatory expertise for small/start-up, as well as large pharma companies.

Read More

Milton Grannatt

Milton Grannatt, Ph.D

Retired Vice President, Global Business Development & Licensing, Novartis

Board Member

Dr. Grannatt retired September 2012 after 25 years in the global pharmaceuticals industry. He was Vice President of Global Business Development and Licensing at Novartis. Prior to Novartis, he held senior positions at Sterling Winthrop and Lex Service, an acquisitive, diversified UK-based company. Dr. Grannatt has an extensive deal sheet.

Read More

Casey Case

Casey Case, Ph.D.

Senior Vice President, 4D Molecular Therapeutics

Board Member

Dr. Casey Case is a veteran pharmaceutical industry executive. He has contributed to the success of biopharmaceutical companies such as OSI Pharmaceuticals, Tularik and Sangamo Biosciences. 

Read More

Hemant N. Joshi

Hemant N. Joshi, Ph.D., MBA

Founder, TARA Innovations, LLC.


Dr. Hemant Joshi is the founder of Tara Innovations LLC, a Pharmaceutical product development Contract Research Organization (CRO). He has over 27 years' experience as a Pharmaceutical Scientist. Tara is involved in product development, analysis and technology management.

Read More

Paul Jeffrey

Paul Jeffrey, M.B.A.

Former Vice President, New Product Development & Commercialization, Pfizer

Board Member

Mr. Paul Jeffrey is an experienced business executive and advisor with over 35 years of pharmaceutical research, product development, marketing and business development experience. As vice president of early commercial development at Pfizer, he was responsible for the commercial development of the entire portfolio of Rx pipeline products in Primary Care.

Read More

Clifford M. Davidson

Clifford M. Davidson

Intellectual Property Attorney, Founding Partner, Davidson, Davidson & Kappel, LLC


Cliff Davidson is a founding partner at Davidson, Davidson & Kappel, LLC, an Intellectual Property law firm with offices in New York. He counsels pharmaceutical clients in pharmaceutical patent-related matters, including patent prosecution, freedom to operate and infringement opinions, due diligence and tech transfer, and litigation. He has assisted pharmaceutical and biotech companies in creating significant and valuable patent portfolios covering their proprietary technologies.

Read More